Literature DB >> 1603244

A community-based study of dementia: the Rotterdam Elderly Study.

M M Breteler1, F A van den Ouweland, D E Grobbee, A Hofman.   

Abstract

The Rotterdam Elderly Study is designed as a community-based prospective follow-up study. The study population consists of almost 12,000 individuals aged 55 years and over who are living in an urban area in Rotterdam, the Netherlands. The objective of the study is to investigate the prevalence, incidence and determinants of neurogeriatric disorders, cardiovascular diseases, locomotor diseases and ophthalmologic diseases. In this paper we give a general outline of the Rotterdam Elderly Study, and a detailed description of the case finding and diagnostic procedures for the study of dementia. The risk factors for dementia that are assessed in the study are summarized.

Entities:  

Mesh：

Year:  1992        PMID： 1603244     DOI： 10.1159/000110957

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN： 0251-5350            Impact factor:   3.282


  18 in total

Review 1.  Health status assessment of the elderly.

Authors:  I Turpie; D Strang; P Darzins; G Guyatt
Journal:  Pharmacoeconomics       Date:  1997-11       Impact factor: 4.981

2.  The PREMAP Study: prevalence and risk factors of dementia and clinically diagnosed Alzheimer's disease in Provence, France. Prevalence of Alzheimer's Disease in Provence.

Authors:  Y Obadia; M Rotily; A Degrand-Guillaud; J Guelain; M Ceccaldi; C Severo; M Poncet; A Alperovitch
Journal:  Eur J Epidemiol       Date:  1997-04       Impact factor: 8.082

3.  Estimated life expectancy of Parkinson's patients compared with the UK population.

Authors:  Lianna S Ishihara; Anne Cheesbrough; Carol Brayne; Anette Schrag
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-30       Impact factor: 10.154

4.  Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics.

Authors:  Tamara B Harris; Lenore J Launer; Gudny Eiriksdottir; Olafur Kjartansson; Palmi V Jonsson; Gunnar Sigurdsson; Gudmundur Thorgeirsson; Thor Aspelund; Melissa E Garcia; Mary Frances Cotch; Howard J Hoffman; Vilmundur Gudnason
Journal:  Am J Epidemiol       Date:  2007-03-10       Impact factor: 4.897

5.  Vascular risk factors, atherosclerosis, cerebral white matter lesions and cerebral perfusion in a population-based study.

Authors:  J J Claus; M M Breteler; D Hasan; E P Krenning; M L Bots; D E Grobbee; J C van Swieten; F van Harskamp; A Hofman
Journal:  Eur J Nucl Med       Date:  1996-06

6.  Prevalence of dementia and major dementia subtypes in Spanish populations: a reanalysis of dementia prevalence surveys, 1990-2008.

Authors:  Jesús de Pedro-Cuesta; Javier Virués-Ortega; Saturio Vega; Manuel Seijo-Martínez; Pedro Saz; Fernanda Rodríguez; Angel Rodríguez-Laso; Ramón Reñé; Susana Pérez de las Heras; Raimundo Mateos; Pablo Martínez-Martín; José María Manubens; Ignacio Mahillo-Fernandez; Secundino López-Pousa; Antonio Lobo; Jordi Llinàs Reglà; Jordi Gascón; Francisco José García; Manuel Fernández-Martínez; Raquel Boix; Félix Bermejo-Pareja; Alberto Bergareche; Julián Benito-León; Ana de Arce; José Luis del Barrio
Journal:  BMC Neurol       Date:  2009-10-19       Impact factor: 2.474

7.  Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study.

Authors:  M M Breteler; J J Claus; D E Grobbee; A Hofman
Journal:  BMJ       Date:  1994-06-18

8.  Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study.

Authors:  A Ott; M M Breteler; F van Harskamp; J J Claus; T J van der Cammen; D E Grobbee; A Hofman
Journal:  BMJ       Date:  1995-04-15

9.  Assessment of cerebral perfusion with single-photon emission tomography in normal subjects and in patients with Alzheimer's disease: effects of region of interest selection.

Authors:  J J Claus; F van Harskamp; M M Breteler; E P Krenning; T J van der Cammen; A Hofman; D Hasan
Journal:  Eur J Nucl Med       Date:  1994-10

Review 10.  Hypertension and cognitive function.

Authors:  Thomas Olabode Obisesan
Journal:  Clin Geriatr Med       Date:  2009-05       Impact factor: 3.076
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.